TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04611126

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Nivolumab 240 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 30 minutes.

Intervention type: DRUG
Group type: OTHER
Intervention: Relatlimab
Description: Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
Study: NCT06644976

Intervention type: PROCEDURE
Intervention: femoral neck CRIF
Description: femoral neck fracture CRiF while under noac. no special intervention beside taking blood test for drug levels

Intervention type: PROCEDURE
Intervention: femoral neck CRIF
Description: femoral neck fracture CRiF while under noac. no special intervention beside taking blood test for drug levels
Study: NCT06643806

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHAI dyad study
Description: In the CHAI (Cardiovascular Health among Asian Indian immigrants) Dyad study, we plan to Implement and pilot test a peer leader-facilitated 12-week dyadic intervention to decrease CVD risk among first generation AI immigrants;

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAI dyad study
Description: In the CHAI (Cardiovascular Health among Asian Indian immigrants) Dyad study, we plan to Implement and pilot test a peer leader-facilitated 12-week dyadic intervention to decrease CVD risk among first generation AI immigrants;
Study: NCT05804084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide tablet (encapsulated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide tablet (encapsulated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule manufactured to match encapsulated Acetazolamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar capsule manufactured to match encapsulated Acetazolamide
Study: NCT05794230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Liquid solution - intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Liquid solution - intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: Liquid solution - intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: Liquid solution - intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Description: Oral suspension - oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Description: Oral suspension - oral

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Description: Oral suspension - oral

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV)
Description: Oral suspension - oral

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumoccocal Vaccine
Description: Suspension for injection - intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, and Rubella Vaccine live (MMR)
Description: Lyophilized powder for injection - subcutaneous

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles, Mumps, and Rubella Vaccine live (MMR)
Description: Lyophilized powder for injection - subcutaneous
Study: NCT04611126

Intervention type: DRUG
Group type: OTHER
Intervention: Relatlimab
Description: Relatlimab 80 mg i.v. is administered on day -2 and every 2 weeks for a total of 4 doses. The medicine is administered over 60 minutes.
Study: NCT05794230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Vaccine live (MMR)
Description: Lyophilized powder for injection - subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Vaccine live (MMR)
Description: Lyophilized powder for injection - subcutaneous
Study: NCT05109559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose of Ad26.COV2. 5x10^10vp
Description: A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
Study: NCT05794230

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTwP-HepB-Hib-IPV vaccine
Description: Suspension - intramuscular

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTwP-HepB-Hib-IPV vaccine
Description: Suspension - intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib-IPV vaccine
Description: Suspension - intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-HepB-Hib-IPV vaccine
Description: Suspension - intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-IPV-Hib-HepB vaccine
Description: Liquid solution - intramuscular
Study: NCT05794230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib-HepB vaccine
Description: Liquid solution - intramuscular

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP-IPV-Hib-HepB vaccine
Description: Liquid solution - intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib-HepB vaccine
Description: Liquid solution - intramuscular
Study: NCT05109559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Half dose of Ad26.COV2. 2.5x10^10vp
Description: A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full dose of Ad26.COV2. 5x10^10vp
Description: A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.
Study: NCT06564532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluatively conditioning participant to like partner
Description: The intervention is a computerized learning task that leads the participant to associate the partner with positive stimuli

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluatively conditioning participant to like partner
Description: The intervention is a computerized learning task that leads the participant to associate the partner with positive stimuli
Study: NCT05794230

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Lyophilized powder for injection - subcutaneous

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis A vaccine
Description: Lyophilized powder for injection - subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Lyophilized powder for injection - subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine
Description: Lyophilized powder for injection - subcutaneous
Study: NCT06564532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluatively conditioning partner to like participant
Description: The intervention is a computerized learning task that leads the partner to associate the participant with positive stimuli

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluatively conditioning partner to like participant
Description: The intervention is a computerized learning task that leads the partner to associate the participant with positive stimuli
Study: NCT06371482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is an immunoglobulin G (IgG) 1-κsubtype monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 in T cells and CD80 (B7.1) in immune cells (ics). Durvalumab is developed by Astrazeneca /MedImmune for the treatment of cancer. Durvalumab is designed to reduce the cytotoxicity of antibody-dependent cells and complement dependent cytotoxicity. In vitro studies have demonstrated that Durvalumab can antagonize the inhibition of PD-L1 in human primary T cells, causing them to resume proliferation and release interferon gamma (IFNγ). To date, more than 1,800 patients have been treated with valiuzumab as a single agent or in combination with other cancer agents as part of ongoing studies. Durvalumab: 10mg/Kg, intravenously, starting at week 7 every 3 weeks for at least 1 year, or until progression, intolerance, or spontaneous withdrawal of the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug of EP regimen
Description: Etoposide: 80-100mg/m², intravenous infusion, given at week 1, 4, 7, 10, 13, 16, a total of 6 cycles.~Carboplatin: AUC=5-6, intravenous infusion, given at weeks 1, 4, 7, 10, 13, 16, a total of 6 weeks. Or cisplatin: 75-80mg/m2 intravenously, given at weeks 1, 4, 7, 10, 13, 16 for a total of 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy: Total dose of 60Gy/30 times, each time 2.0Gy, 5 times a week from week 7 to week 12 of radiotherapy.
Study: NCT06170060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic sleeve gastrectomy (LSG) is a surgical procedure widely used in the treatment of obesity. It's a bariatric procedure, meaning its primary aim is to induce weight loss, and it has gained popularity due to its effectiveness and relatively low complication rates compared to other bariatric surgeries.
Study: NCT04906382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT05794230

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine
Description: Oral solution - oral

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine
Description: Oral solution - oral

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavirus vaccine
Description: Oral solution - oral
Study: NCT06629740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements with a eHealth system
Description: The eHealth system Previct Drugs is a CE marked medical device intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. Previct Drugs consists of a mobile phone application used to perform self-administered eye-scanning, a web-based careportal used by the caregiver, a database for storage, handling, and analysis of reported data, and an admin portal for the manufacturer to register and administer customers. In this study, Previct Drugs will be used by healthy volunteers for performing measurements before and after intake of a commonly used medicine to simulate drug intake.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements with a eHealth system
Description: The eHealth system Previct Drugs is a CE marked medical device intended to be used in treatment of substance use disorder (SUD) to support and monitor patients' treatment. Previct Drugs consists of a mobile phone application used to perform self-administered eye-scanning, a web-based careportal used by the caregiver, a database for storage, handling, and analysis of reported data, and an admin portal for the manufacturer to register and administer customers. In this study, Previct Drugs will be used by healthy volunteers for performing measurements before and after intake of a commonly used medicine to simulate drug intake.
Study: NCT05165225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
Description: Drug: Pyrotinib pyrotinib 320mg orally daily Drug: Epirubicin epirubicin 90mg/m\^2 d1 iv Q3W for 4 cycles Drug: Cyclophosphamide cyclophosphamide 600mg/m\^2 d1 iv Q3W for 4 cycles Drug: Docetaxel docetaxel 100mg/m\^2 d1 iv Q3W for 4 cycles
Study: NCT05132868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video and pamphlet
Description: The primary intervention in this study is watching the video or reading the pamphlet in advance of the genetic counseling session, which overview the same information that we currently provide in-person/via telehealth during the genetic counseling session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video and pamphlet
Description: The primary intervention in this study is watching the video or reading the pamphlet in advance of the genetic counseling session, which overview the same information that we currently provide in-person/via telehealth during the genetic counseling session.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional genetic counseling
Description: Patients will receive traditional genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional genetic counseling
Description: Patients will receive traditional genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional genetic counseling
Description: Patients will receive traditional genetic counseling
Study: NCT05307978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1910
Description: Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1910
Description: Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1910
Description: Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1910
Description: Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1910
Description: Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1910
Description: Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo IV or Placebo SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo IV or Placebo SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo IV or Placebo SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo IV or Placebo SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo IV or Placebo SC according to their assigned cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive Placebo IV or Placebo SC according to their assigned cohort.
Study: NCT05374668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based Yoga Exercises
Description: They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based Yoga Exercises
Description: They were trained face-to-face with social distancing and a maximum of three participants. They were observed while practicing and necessary alerts and corrections were made. Documents related to the videos for yoga exercises and posture exercises specially prepared for this study by the qualified physiotherapist (MD) were provided to the participants
Study: NCT06415318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Ifosfamide + Cisplatin & Toripalimab
Description: Paclitaxel + Ifosfamide + Cisplatin \& Toripalimab
Study: NCT05554939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic CD19-CAR-γδT cell
Description: Phase 1 dose escalation (3+3) : dose 1 (6 × 10\^6 cells/kg) , dose 2 (1.2 × 10\^7 cells/kg), dose 3 (1.8 × 10\^7 cells/kg); Phase 2 : dose of RP2D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Intravenous fludarabine 30\~50 mg/m\^2/day on days -5, -4, and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous cyclophosphamide 500\~1000 mg/m\^2/day on days -5, -4, and -3.
Study: NCT06302985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: atomized inhalation ICG before thoracoscope pneumonectomy
Description: Preoperative preparation ICG solution dissolved in 5ml of normal saline (dose 0.5mg/kg) was inhaled 30 minutes before surgery.~Operation method After entering the chest cavity, the fluorescence endoscope was switched to the fluorescence display mode, and the fluorescence-stained normal lung tissue and non-stained lesion tissue could be clearly displayed through the display screen, and the external boundary of the lesion was marked with an electric hook. The mediastinal pleura and pulmonary pleura were opened along the boundary of the lesion, and the lung tissue was split along the gap between the lesion and the lung tissue with an electric coagulation hook and an ultrasonic knife, and the lesion arteries and bronchi were freed.
Study: NCT06024538

Intervention type: PROCEDURE
Intervention: Tumor samples
Description: Tumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
Study: NCT04906382

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Given IV
Study: NCT05599269

Intervention type: DEVICE
Group type: OTHER
Intervention: Examination of dentures with SR Phonares II teeth
Description: The intraoral situation will be examined similar to a standard dental examination. The dentures are then removed, cleaned and examined extraoral. Pictures and an impression of the dentures are taken.
Study: NCT05650060

Intervention type: DRUG
Intervention: Secukinumab
Description: all patients with psoriasis who received secukinumab
Study: NCT06379087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit simultaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Injection
Description: Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody.
Study: NCT05203055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b
Description: 180μg/w
Study: NCT06379087

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Hypofractionated Radiotherapy Extent of radiotherapy: Primary lesion in the lung. Radiotherapy technique: IGRT. Radiotherapy delivery equipment: linear accelerator or TOMO accelerator or CyberKnife.
Study: NCT05452772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Participants will received two psilocybin sessions, 1 week apart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: Participants will received two niacin sessions, 1 week apart
Study: NCT05264415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC)
Description: Trauma-informed, family-centered, skill-building preventive intervention for families with preschool-aged children.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Education Website
Description: A website providing parenting education resources in four primary domains relevant for families with preschool-aged children (parenting, child development, transitions, and self-care).
Study: NCT06259084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seedchrony
Description: The seedchrony probe is coupled to the transfer catheter. When the transfer catheter is placed inside the uterus, the probe measures the biomarker concentraction in the fluid entering the catheter. The measurements last two minutes.
Study: NCT04634838

Intervention type: DEVICE
Group type: OTHER
Intervention: MedCu Antibacterial Wound Dressings with Copper Oxide
Description: Comparison between the efficacy of antibacterial wound dressings containing copper oxide microparticles to improve the wound healing of pressure sores and post-op wounds as compared to silver wound dressings
Study: NCT05203055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b
Description: 180μg/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2b
Description: 180μg/w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleotide Analog
Description: Etecavir 0.5mg qd or Tenofovir 300mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pulse peginterferon alpha-2b
Description: 180μg/w for 8 consecutive weeks and cessation for 4 weeks
Study: NCT06053463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daily disposable multifocal soft contact lens
Description: Daily disposable multifocal soft contact lens that will be worn for 1 month.